Click on a filter below to refine your search. Remove a filter to broaden your search.
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.
COVID-19 will remain the third-largest killer for 2022, behind heart disease and cancer, even with the reduced numbers.
The findings were seen regardless of vaccination status and history of prior infection.
But the myocarditis risk was higher after vaccination for men younger than age 40 years, particularly after the second dose of mRNA-1273.
COVID-19 deaths have fallen sharply as vaccination rates have surged in recent months.